In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Idexx Laboratories, Inc (NASDAQ: IDXX) closed at $663.92 up 1.79% from its previous closing price of $652.27. In other words, the price has increased by $1.79 from its previous closing price. On the day, 0.57 million shares were traded. IDXX stock price reached its highest trading level at $665.025 during the session, while it also had its lowest trading level at $648.92.
Ratios:
For a deeper understanding of Idexx Laboratories, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 322.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 67.72. For the most recent quarter (mrq), Quick Ratio is recorded 0.74 and its Current Ratio is at 1.06. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on August 05, 2025, Reiterated its Buy rating but revised its target price to $785 from $545 previously.
On July 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $625.
On December 02, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $500.Leerink Partners initiated its Outperform rating on December 02, 2024, with a $500 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 11 ’25 when Hunt Nimrata sold 1,200 shares for $656.53 per share. The transaction valued at 787,840 led to the insider holds 16,807 shares of the business.
MICHAEL G ERICKSON bought 407 shares of IDXX for $264,534 on Aug 12 ’25. On Aug 08 ’25, another insider, Underberg Sharon E., who serves as the EVP, GC & Corporate Secretary of the company, sold 5,450 shares for $651.60 each. As a result, the insider received 3,551,220 and left with 6,156 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IDXX now has a Market Capitalization of 53116723200 and an Enterprise Value of 54189391872. As of this moment, Idexx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 55.26, and their Forward P/E ratio for the next fiscal year is 46.93. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.78. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.16 while its Price-to-Book (P/B) ratio in mrq is 36.48. Its current Enterprise Value per Revenue stands at 13.421 whereas that against EBITDA is 38.906.
Stock Price History:
The Beta on a monthly basis for IDXX is 1.56, which has changed by 0.36744106 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, IDXX has reached a high of $688.12, while it has fallen to a 52-week low of $356.14. The 50-Day Moving Average of the stock is 20.06%, while the 200-Day Moving Average is calculated to be 42.15%.
Shares Statistics:
For the past three months, IDXX has traded an average of 603.09K shares per day and 1074200 over the past ten days. A total of 80.15M shares are outstanding, with a floating share count of 79.20M. Insiders hold about 1.00% of the company’s shares, while institutions hold 96.63% stake in the company. Shares short for IDXX as of 1753920000 were 2481513 with a Short Ratio of 4.11, compared to 1751241600 on 2545506. Therefore, it implies a Short% of Shares Outstanding of 2481513 and a Short% of Float of 4.0599998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Idexx Laboratories, Inc (IDXX) is the result of assessments by 10.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $2.9, with high estimates of $3.02 and low estimates of $2.72.
Analysts are recommending an EPS of between $12.88 and $12.32 for the fiscal current year, implying an average EPS of $12.57. EPS for the following year is $14.06, with 12.0 analysts recommending between $14.37 and $13.18.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $1.07B this quarter.It ranges from a high estimate of $1.08B to a low estimate of $1.06B. As of the current estimate, Idexx Laboratories, Inc’s year-ago sales were $975.54MFor the next quarter, 9 analysts are estimating revenue of $1.05B. There is a high estimate of $1.07B for the next quarter, whereas the lowest estimate is $1.04B.
A total of 12 analysts have provided revenue estimates for IDXX’s current fiscal year. The highest revenue estimate was $4.26B, while the lowest revenue estimate was $4.2B, resulting in an average revenue estimate of $4.23B. In the same quarter a year ago, actual revenue was $3.9BBased on 12 analysts’ estimates, the company’s revenue will be $4.58B in the next fiscal year. The high estimate is $4.64B and the low estimate is $4.5B.
